▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2175 by analyst upside · 2026-11-14
BNTX
BioNTech SE
Healthcare · Market Cap $21B · P/E 0x
ANALYST PRICE TARGET
+31.3%
implied upside to consensus target
Current Price $85.6
Consensus Target $112.4
Bull Target $144.39
Bear Target $74.68
Analysts Covering 20
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
12
Hold
7
Sell
0
52-Week Low $79.52
52-Week High $124.0
YTD Return -11.5%
FUNDAMENTALS
Market Cap $21B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-6.88
PEG Ratio 0.05
Dividend Yield N/A
Revenue (TTM) $2.4B
Profit Margin -60.9%
52-WEEK RANGE
52-Week Low $79.52
52-Week High $124.0
Current Price $85.6
Bear Target $74.68
Bull Target $144.39
● Now $85.6 ● Target $112.4
TRADING DATA
Avg Volume 1.2M
YTD Return -11.5%
Analyst Count 20
Consensus Buy
Upside to Target +31.3%
Last Updated 2026-11-14

ANALYST SUMMARY

BioNTech SE (BNTX) is currently trading at $85.6 with a Wall Street consensus price target of $112.4, implying potential upside of 31.3% over the next 12 months. 20 analysts currently cover BNTX, with a consensus rating of Buy - 65% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $144.39, while the most cautious has a target of $74.68.

BNTX operates in the Healthcare sector with a market capitalisation of $21B. The stock is down 11.5% year-to-date and is currently trading near the lower end of its 52-week range of $79.52 – $124.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for BNTX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

UBS - Reiterated
Buy → Buy 2026-11-04 33% win rate (6 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-11-04 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-11-04 Building track record
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-11-04 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2026-10-14 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2026-10-07 Building track record
BMO Capital ↓ Downgrade
Outperform → Market Perform 2026-09-08 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2026-08-31 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
51
out of 100
Coverage depth
23/30
Consensus clarity
14/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →